[18F]FDG PET/CT作为早期乳腺癌新辅助治疗疗效评估的生物标志物:能否在兴起的降阶梯策略场景中成为变革者
本文综述了[18F]FDG PET/CT在早期乳腺癌新辅助系统治疗疗效评估中的价值。该检查在预测和评估乳腺及淋巴结病理完全缓解方面通常显示较好的敏感度但特异度较低,可能支持对代谢反应不佳者及时升级系统治疗或手术。但现有研究样本小、异质性大,国际指南尚不一致,需进一步证据明确其作用。
要点
- [18F]FDG PET/CT预测和评估病理完全缓解时敏感度较好但特异度较低。
- 代谢反应不佳者可能据此及时升级系统治疗或手术。
- 现有研究样本小且异质,国际指南尚不一致,需进一步证据。
核心结论
- 综述显示[18F]FDG PET/CT在乳腺和淋巴结中预测及评估病理完全缓解时通常敏感度较好但特异度较低,可能支持对代谢反应不佳者及时升级系统治疗或手术,但需进一步证据明确其作用。
研究设计与样本
- 通过全面复习现有文献进行的综述,纳入研究样本小且异质,患者选择、检查时机和反应定义各异。
关键影像表现/征象
- [18F]FDG PET/CT在乳腺和淋巴结中评估新辅助治疗期间及术前的病理完全缓解。
诊断标准与关键数值
- 预测病理完全缓解时敏感度较好但特异度较低。
- 评估病理完全缓解时敏感度较好但特异度较低。
临床应用与阅片要点
- 作者认为该检查可能支持对代谢反应不佳者及时升级系统治疗或手术。
- 国际指南对[18F]FDG PET/CT在疗效评估中的作用尚不一致。
局限性
- 现有研究样本小。
- 研究异质性大,患者选择、检查时机和反应定义各异。
- 国际指南尚不一致。
- 需进一步证据明确其在疗效评估中的作用、最佳临床实践应用及如何整合入降阶梯策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Over the past decades, neoadjuvant systemic treatment (NAT) has been increasingly adopted in early-stage breast cancer (BC), highlighting the need for a more accurate assessment of treatment response. Imaging tools such as [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography combined with computed tomography (PET/CT) may enhance diagnostic accuracy in this context. By comprehensively reviewing the available literature, [18F]FDG PET/CT generally shows good sensibility but lower specificity for predicting and evaluating pathological complete response (pCR), respectively, during NAT and preoperatively, in both the breast and lymph nodes. Thereby its use may support timely escalation of systemic treatment or surgery in patients with poor metabolic response. However, definitive conclusions are limited by small, heterogeneous studies with variable patient selection, timing, and response definitions. Consequently, while international guidelines remain inconsistent, further evidence is needed to define its role in response assessment, establish the optimal use in clinical practice, and clarify its integration into (de)-escalation strategies.
引用
- Gerosa R, Gelardi F, Tiberio P, et al. [18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies? Radiol Med. 2025. PMID: 41324775. doi:10.1007/s11547-025-02138-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。